Trial Profile
Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2013
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 23 Oct 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.